The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 33, No. 11, pp. 1184-1188. DOI 10.1345/aph.19008
© 1999 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by DeVincenzo, J.
Right arrow Articles by Husson, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DeVincenzo, J.
Right arrow Articles by Husson, R.

Research Articles

Multidrug-resistant tuberculosis meningitis: clinical problems and concentrations of second-line antituberculous medications

JP DeVincenzo, SE Berning, CA Peloquin, and RN Husson

OBOFFTIVE: To describe a case of culture-proven multidrug-resistant tuberculous (MDR-TB) meningitis, in which the patient survived long enough for clinicians to adjust antituberculous therapy to second-line therapeutic agents. DESIGN: Case report. SETTING: Tertiary care hospital. PATIENT: Twenty-one-month-old girl with MDR-TB meningitis. INTERVENTIONS: Initial standard treatment failed. Subsequent treatment with second-line therapeutic agents including ciprofloxacin, cycloserine, ethambutol, ethionamide, and rifabutin were given for approximately two years. Concentrations of these drugs were measured in serum and cerebrospinal fluid in the presence and absence of meningeal inflammation. MAIN OUTCOME MEASURES/RESULTS: The patient survived for approximately two years after initiation of second-line anti-TB therapy. During this treatment, she developed a ventriculo-peritoneal shunt tunnel tract infection secondary to MDR-TB. CONCLUSIONS: All TB meningitis isolates for which the source case antibiotic susceptibility pattern is not known should be cultured and susceptibility tested using rapid broth techniques. Measurement and subsequent adjustment of therapeutic drug concentrations may optimize therapy with second-line anti-TB drugs in TB meningitis. Better pediatric formulations and pharmacokinetic data for second-line and anti-TB therapeutic agents are needed.


This article has been cited by other articles:


Home page
 J. Clin. Microbiol.Home page
A. Upton, A. Woodhouse, R. Vaughan, S. Newton, and R. Ellis-Pegler
Evolution of Central Nervous System Multidrug-Resistant Mycobacterium tuberculosis and Late Relapse of Cryptic Prosthetic Hip Joint Tuberculosis: Complications during Treatment of Disseminated Isoniazid-Resistant Tuberculosis in an Immunocompromised Host
J. Clin. Microbiol., February 1, 2009; 47(2): 507 - 510.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
R. B. Rock, M. Olin, C. A. Baker, T. W. Molitor, and P. K. Peterson
Central Nervous System Tuberculosis: Pathogenesis and Clinical Aspects
Clin. Microbiol. Rev., April 1, 2008; 21(2): 243 - 261.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 1999 by Harvey Whitney Books Company.